Related references
Note: Only part of the references are listed.Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z. Usmani et al.
LANCET ONCOLOGY (2022)
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Katja Weisel et al.
LEUKEMIA & LYMPHOMA (2022)
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jianming He et al.
ADVANCES IN THERAPY (2022)
Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Meletios A. Dimopoulos et al.
BLOOD (2022)
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation
Surbhi Sidana et al.
TRANSPLANTATION AND CELLULAR THERAPY (2022)
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Hannah M. Cherniawsky et al.
HAEMATOLOGICA (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2021)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Philippe Moreau et al.
LANCET ONCOLOGY (2021)
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
Catherine S. Y. Lecat et al.
FRONTIERS IN ONCOLOGY (2021)
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Maria-Victoria Mateos et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
David S. Siegel et al.
LEUKEMIA (2020)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos et al.
LANCET (2020)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson et al.
LANCET ONCOLOGY (2019)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Clinical course of patients with relapsed multiple myeloma
SK Kumar et al.
MAYO CLINIC PROCEEDINGS (2004)
Share Paper
